Shots:

• Novo Nordisk to acquire all outstanding shares of Forma Therapeutics’ common stock at $20/share in cash representing a total equity value of $1.1B and a premium of 92% to Forma Therapeutics’ volume-weighted avg. price/share over the past 30 days. The acquisition is expected to close in Q4’22
• The acquisition will strengthen Novo Nordisk’s strategy to advance the scientific presence and pipeline in haemoglobinopathies with the addition of etavopivat for patients with SCD and rare blood disorders
• Etavopivat is a selective PKR activator & is currently being studied in the P-II/III trial for SCD, and P-II trial for transfusion-dependent SCD and another inherited haemoglobinopathy

Ref: GlobeNewswire | Image: Novo Nordisk